Exomir-122-5p also targets genes like Glucose-6-Phosphate Catalytic Subunit 3 (G6PC3) and Farnesyl-diphosphate farnesyltransferase 1 (FDFT1) essential for hydrolysis of glucose 6-phosphate in glycolysis and cholesterol biosynthesis respectively, impairing their proper functioning and leading to insulin resistance (44) and hence, GDM in patients. The gene discussed is FDFT1; the disease is Insulin resistance.